FDA to Review Moderna mRNA Flu Vaccine Safety Data
Published Date: 5/22/2026
Notice
Summary
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Advisory Review of Moderna mRNA Flu Vaccine
If you are 50 years of age or older, FDA's advisory committee will meet on June 18, 2026 to discuss the safety and effectiveness of MFLUSIVA (an mRNA influenza vaccine manufactured by Moderna) for preventing influenza A and B. The public docket for comments (Docket No. FDA-2026-N-4162) closes June 17, 2026, and comments received by June 12, 2026 will be provided to the Committee.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2026-10320 — Caribbean Fishery Management Council's Outreach and Education Advisory Panel; Public Hybrid Meeting
The Caribbean Fishery Management Council’s Outreach and Education Advisory Panel is hosting a hybrid public meeting on June 24, 2026, to discuss fishery education and outreach plans affecting local fishing communities and stakeholders. This meeting offers a chance to join in person or online, making it easier for everyone to get involved and stay informed about upcoming changes and initiatives. No direct costs or new rules are announced yet, but it’s a key step in shaping future fishery programs.
Next: 2026-10322 — Magnuson-Stevens Act Provisions; General Provisions for Domestic Fisheries; Application for Exempted Fishing Permits
The government is reviewing a special fishing permit request that would let certain boats fish in areas usually off-limits to protect habitats. This permit supports a project by the Coonamessett Farm Foundation to use clam dredges in the Great South Channel Habitat Management Area. People have until June 8, 2026, to share their thoughts, and this could change how some fishing rules apply, but no new fees are mentioned.